

## FARICIMAB solution for injection (Vabysmo® ▼) for neovascular (wet) age-related macular degeneration

**The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of FARICIMAB solution for injection (Vabysmo® ▼) for neovascular (wet) age-related macular degeneration.**

### GREY

Faricimab is indicated for the treatment adults with neovascular (wet) age-related macular degeneration (AMD).<sup>[1]</sup>

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, treatment of neovascular (wet) AMD should continue to follow national guidance, local pathways and local formulary choices:

- > NICE Guideline NG82: [Age-related macular degeneration](#) (23 January 2018)
- > Pan Mersey APC Formulary: [Chapter 11.08.02: Subfoveal choroidal neovascularisation](#)

### References

1. Roche Products Limited. Summary of Product Characteristics; [Vabysmo 120 mg/mL solution for injection](#), 16 May 2022. Accessed 21 June 2022.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.